180 related articles for article (PubMed ID: 25993174)
21. Multigene clinical mutational profiling of breast carcinoma using next-generation sequencing.
Roy-Chowdhuri S; de Melo Gagliato D; Routbort MJ; Patel KP; Singh RR; Broaddus R; Lazar AJ; Sahin A; Alvarez RH; Moulder S; Wheler JJ; Janku F; Gonzalez-Angulo AM; Chavez-MacGregor M; Valero V; Ueno NT; Mills G; Mendelsohn J; Yao H; Aldape K; Luthra R; Meric-Bernstam F
Am J Clin Pathol; 2015 Nov; 144(5):713-21. PubMed ID: 26486734
[TBL] [Abstract][Full Text] [Related]
22. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
Nahta R; O'Regan RM
Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425
[TBL] [Abstract][Full Text] [Related]
23. Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
Toomey S; Eustace AJ; Fay J; Sheehan KM; Carr A; Milewska M; Madden SF; Teiserskiene A; Kay EW; O'Donovan N; Gallagher W; Grogan L; Breathnach O; Walshe J; Kelly C; Moulton B; Kennedy MJ; Gullo G; Hill AD; Power C; Duke D; Hambly N; Crown J; Hennessy BT
Breast Cancer Res; 2017 Jul; 19(1):87. PubMed ID: 28750640
[TBL] [Abstract][Full Text] [Related]
24. Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition: a breakthrough in the management of luminal (ER+/HER2-) breast cancers?
Zardavas D; Fumagalli D; Loi S
Curr Opin Oncol; 2012 Nov; 24(6):623-34. PubMed ID: 22960556
[TBL] [Abstract][Full Text] [Related]
25. Array CGH and PIK3CA/AKT1 mutations to drive patients to specific targeted agents: a clinical experience in 108 patients with metastatic breast cancer.
Arnedos M; Scott V; Job B; De La Cruz J; Commo F; Mathieu MC; Wolp-Diniz R; Richon C; Campone M; Bachelot T; Dalenc F; Dessen P; Lacroix L; Lazar V; Soria JC; Delaloge S; Andre F
Eur J Cancer; 2012 Oct; 48(15):2293-9. PubMed ID: 22840369
[TBL] [Abstract][Full Text] [Related]
26. Targeted therapy for breast cancer.
Mohamed A; Krajewski K; Cakar B; Ma CX
Am J Pathol; 2013 Oct; 183(4):1096-1112. PubMed ID: 23988612
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.
Razis E; Bobos M; Kotoula V; Eleftheraki AG; Kalofonos HP; Pavlakis K; Papakostas P; Aravantinos G; Rigakos G; Efstratiou I; Petraki K; Bafaloukos D; Kostopoulos I; Pectasides D; Kalogeras KT; Skarlos D; Fountzilas G
Breast Cancer Res Treat; 2011 Jul; 128(2):447-56. PubMed ID: 21594665
[TBL] [Abstract][Full Text] [Related]
28. Targeted NGS, array-CGH, and patient-derived tumor xenografts for precision medicine in advanced breast cancer: a single-center prospective study.
Gonçalves A; Bertucci F; Guille A; Garnier S; Adelaide J; Carbuccia N; Cabaud O; Finetti P; Brunelle S; Piana G; Tomassin-Piana J; Paciencia M; Lambaudie E; Popovici C; Sabatier R; Tarpin C; Provansal M; Extra JM; Eisinger F; Sobol H; Viens P; Lopez M; Ginestier C; Charafe-Jauffret E; Chaffanet M; Birnbaum D
Oncotarget; 2016 Nov; 7(48):79428-79441. PubMed ID: 27765906
[TBL] [Abstract][Full Text] [Related]
29. Role of HER2 mutations in refractory metastatic breast cancers: targeted sequencing results in patients with refractory breast cancer.
Park YH; Shin HT; Jung HH; Choi YL; Ahn T; Park K; Lee A; Do IG; Kim JY; Ahn JS; Park WY; Im YH
Oncotarget; 2015 Oct; 6(31):32027-38. PubMed ID: 26397225
[TBL] [Abstract][Full Text] [Related]
30. Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women.
Deng L; Chen J; Zhong XR; Luo T; Wang YP; Huang HF; Yin LJ; Qiu Y; Bu H; Lv Q; Zheng H
PLoS One; 2015; 10(3):e0120511. PubMed ID: 25816324
[TBL] [Abstract][Full Text] [Related]
31. Enrichment of PI3K-AKT-mTOR Pathway Activation in Hepatic Metastases from Breast Cancer.
Pierobon M; Ramos C; Wong S; Hodge KA; Aldrich J; Byron S; Anthony SP; Robert NJ; Northfelt DW; Jahanzeb M; Vocila L; Wulfkuhle J; Gambara G; Gallagher RI; Dunetz B; Hoke N; Dong T; Craig DW; Cristofanilli M; Leyland-Jones B; Liotta LA; O'Shaughnessy JA; Carpten JD; Petricoin EF
Clin Cancer Res; 2017 Aug; 23(16):4919-4928. PubMed ID: 28446508
[No Abstract] [Full Text] [Related]
32. Next generation sequencing in cancer: opportunities and challenges for precision cancer medicine.
Paolillo C; Londin E; Fortina P
Scand J Clin Lab Invest Suppl; 2016; 245():S84-91. PubMed ID: 27542004
[TBL] [Abstract][Full Text] [Related]
33. Intratumoral heterogeneity and subclonal diversification of early breast cancer.
Yates LR
Breast; 2017 Aug; 34 Suppl 1():S36-S42. PubMed ID: 28666921
[TBL] [Abstract][Full Text] [Related]
34. The genomic landscape of breast cancer and its interaction with host immunity.
Luen S; Virassamy B; Savas P; Salgado R; Loi S
Breast; 2016 Oct; 29():241-50. PubMed ID: 27481651
[TBL] [Abstract][Full Text] [Related]
35. Standard and Genomic Tools for Decision Support in Breast Cancer Treatment.
Henry NL; Bedard PL; DeMichele A
Am Soc Clin Oncol Educ Book; 2017; 37():106-115. PubMed ID: 28561710
[TBL] [Abstract][Full Text] [Related]
36. Genomic Characterization of Primary Invasive Lobular Breast Cancer.
Desmedt C; Zoppoli G; Gundem G; Pruneri G; Larsimont D; Fornili M; Fumagalli D; Brown D; Rothé F; Vincent D; Kheddoumi N; Rouas G; Majjaj S; Brohée S; Van Loo P; Maisonneuve P; Salgado R; Van Brussel T; Lambrechts D; Bose R; Metzger O; Galant C; Bertucci F; Piccart-Gebhart M; Viale G; Biganzoli E; Campbell PJ; Sotiriou C
J Clin Oncol; 2016 Jun; 34(16):1872-81. PubMed ID: 26926684
[TBL] [Abstract][Full Text] [Related]
37. Personalized medicine for metastatic breast cancer.
Chen TW; Bedard PL
Curr Opin Oncol; 2013 Nov; 25(6):615-24. PubMed ID: 24097103
[TBL] [Abstract][Full Text] [Related]
38. Exceptional durable response to everolimus in a patient with biphenotypic breast cancer harboring an
Parachoniak CA; Rankin A; Gaffney B; Hartmaier R; Spritz D; Erlich RL; Miller VA; Morosini D; Stephens P; Ross JS; Keech J; Chmielecki J
Cold Spring Harb Mol Case Stud; 2017 Sep; 3(5):. PubMed ID: 28550065
[TBL] [Abstract][Full Text] [Related]
39. The Genomic Landscape of Male Breast Cancers.
Piscuoglio S; Ng CK; Murray MP; Guerini-Rocco E; Martelotto LG; Geyer FC; Bidard FC; Berman S; Fusco N; Sakr RA; Eberle CA; De Mattos-Arruda L; Macedo GS; Akram M; Baslan T; Hicks JB; King TA; Brogi E; Norton L; Weigelt B; Hudis CA; Reis-Filho JS
Clin Cancer Res; 2016 Aug; 22(16):4045-56. PubMed ID: 26960396
[TBL] [Abstract][Full Text] [Related]
40. Mutation matters in precision medicine: A future to believe in.
Dey N; Williams C; Leyland-Jones B; De P
Cancer Treat Rev; 2017 Apr; 55():136-149. PubMed ID: 28371665
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]